Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: An observational study

International Journal of Antimicrobial Agents

Volumn 35, Issue 5, 2010, Pages 468-472

  Myrianthefs, Pavlos ^a   Markantonis, Sophia L ^a   Evaggelopoulou, Penelope ^a   Despotelis, Stratos ^a   Evodia, Effimia ^a   Panidis, Dimitris ^a   Baltopoulos, George ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Critically ill patients; Normal to moderate renal impairment; Pharmacokinetics; Plasma concentration monitoring; Voriconazole

Indexed keywords

COLISTIN; GENTAMICIN; HYDROCORTISONE; VANCOMYCIN; VORICONAZOLE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANDIDEMIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; KIDNEY DYSFUNCTION; LOADING DRUG DOSE; MALE; MINIMUM INHIBITORY CONCENTRATION; OBSERVATIONAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CRITICAL ILLNESS; DRUG MONITORING; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY; KIDNEY FUNCTION TESTS; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PLASMA; PROSPECTIVE STUDIES; PYRIMIDINES; TRIAZOLES;

EID: 77949654401     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.12.021     Document Type: Article

References (27)

1. Blot S., Dimopoulos G., Rello J., Vogelaers D. Is Candida really a threat in the ICU?. Curr Opin Crit Care 2008, 14:600-604.
2. Rüping M.J., Vehreschild J.J., Cornely O.A. Patients at high risk of invasive fungal infections: when and how to treat. Drugs 2008, 68:1941-1962.
3. FDA Antiviral Drugs Advisory Committee. Briefing document for voriconazole (oral and intravenous formulations). FDA Antiviral Drugs Advisory Committee; 2001. [accessed 20 January 2010]. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_Pfizer.pdf.
4. Tomaszewski K., Purkins L. The pharmacokinetics and safety of sulphobutylether-β-cyclodextrin (SBECD). Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 16-19 December 2001, Chicago, IL 2001, Washington, DC, ASM Press, [Abstract 23].
5. Von Mach M.A., Burhenne J., Weilemann L.S. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 2006, 6:6.
6. US Food and Drug Administration. Background document for the Antiviral Drug Products Advisory Committee meeting. FDA; 2001. [accessed 20 January 2010]. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_02_FDA-voriconazole.htm.
7. Abel S., Allan R., Gandelman K., Tomaszewski K., Webb D.J., Wood N.D. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies. Clin Drug Invest 2008, 28:409-420.
8. Hope W.W., Billaud E.M., Lestner J., Denning D.W. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008, 21:580-586.
9. Tan K., Brayshaw N., Tomaszewski K., Troke P., Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006, 46:235-243.
10. Pascual A., Calandra T., Bolay S., Buclin T., Bille J., Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008, 46:201-211.
11. Boyd A.E., Modi S., Howard S.J., Moore C.B., Keevil B.G., Denning D.W. Adverse reactions to voriconazole. Clin Infect Dis 2004, 39:1241-1244.
12. Alvarez-Lerma F., Allepuz-Palau A., Garcia M.P., Angeles Leon M., Navarro A., Sanchez-Ruiz H., et al. Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function. J Chemother 2008, 20:93-100.
13. Gage R., Stopher D.A. A rapid HPLC assay for voriconazole in human plasma. J Pharm Biomed Anal 1998, 17:1449-1453.
14. Trifilio S., Pennick G., Pi J., Zook J., Golf M., Kaniecki K., et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007, 109:1532-1535.
15. Johnson L.B., Kauffman C.A. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003, 36:630-637.
16. Dodds Ashley E.S., Lewis R., Lewis J.S., Martin C., Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006, 43(Suppl. 1):S28-S39.
17. Hyland R., Jones B.C., Smith D.A. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003, 31:540-547.
18. Walsh T.J., Karlsson M.O., Driscoll T., Arguedas A.G., Adamson P., Saez-Llorens X., et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004, 48:2166-2172.
19. Smith J., Safdar N., Knasinski V., Simmons W., Bhavnani S.M., Ambrose P.G., et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006, 50:1570-1572.
20. Denning D.W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34:563-571.
21. Imhof A., Schaer D.J., Schanz U., Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006, 136:739-742.
22. Trifilio S., Ortiz R., Pennick G., Verma A., Pi J., Stosor V., et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005, 35:509-513.
23. Purkins L., Wood N., Ghahramani P., Greenhalgh K., Allen M.J., Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002, 46:2546-2553.
24. Andes D., Marchillo K., Stamstad T., Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003, 47:3165-3169.
25. Pfaller M.A., Diekema D.J., Ostrosky-Zeichner L., Rex J.H., Alexander B.D., Andes D., et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006, 44:819-826.
26. Mohammedi I., Piens M.A., Padoin C., Robert D. Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients. Eur J Clin Microbiol Infect Dis 2005, 24:358-360.
27. Theuretzbacher U., Ihle F., Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006, 45:649-663.